NCT00632762View on ClinicalTrials.gov

Long-Term Effects of Amantadine in Parkinsonian (AMANDYSK)

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Parkinson's Disease
Interventions
DRUG

mantadix

dose greater or equal to 200 mg/day and progressively increasing doses (100mg every 3 days until the pre-study dose is reached).

Trial Locations (5)

13385

CHU Timone, Marseille

13616

Hôpital d'Aix en Provence, Aix-en-Provence

44095

Hôpital Haut-Lévêque, Nantes

63003

CHU de Clermont-Ferrand, Clermont-Ferrand

75013

CHU Pitié-Salpêtrière, Paris

All Listed Sponsors
lead

University Hospital, Toulouse

OTHER

NCT00632762 - Long-Term Effects of Amantadine in Parkinsonian (AMANDYSK) | Biotech Hunter | Biotech Hunter